Recent news on Truvada

THERE ARE MANY STORIES TO TELL ABOUT AIDS PANDEMIC  -  May 23, 2007
VUE Weekly,These drugs, marketed under the names Viread and Truvada, contain a cocktail of several active ingredients known as nucleotide analogue reverse

Botusa Conducts Truvada Clinical Trials  -  May 8, 2007
AllAfrica.com,BOTUSA is conducting clinical trials to see whether Truvada, a combination of two anti-retroviral (ARV) drugs, taken daily can prevent HIV infection.

Tenofovir and Truvada licensed in South Africa  -  Apr 26, 2007
Aidsmap,Tenofovir (Viread) and Truvada will be manufactured and marketed in South Africa by Aspen Pharmacare, which holds a non-exclusive voluntary license for the

Boehringer Ingelheim initiates international head-to-head HIV/AIDS ...  -  May 17, 2007
WebWire (press release),Both agents will be combined with a background regimen including tenofovir and emtricitabine (Truvada®). The ArTEN trial will enroll 561 HIV-positive

Boehringer Ingelheim Initiates International Head-to-Head HIV/AIDS ...  -  May 9, 2007
Juraforum.de,Both agents will becombined with a background regimen including tenofovir andemtricitabine (Truvada(R)). The ArTEN trial will enroll 561HIV-positive

Boehringer Ingelheim Initiates International Head-to-Head HIV/AIDS ...  -  May 9, 2007
PR-Inside.com (Pressemitteilung),The ArTEN (Atazanavir/ritonavir on a background of Tenofovir and Emtricitabine (Truvada) versus Nevirapine) trial is a Phase IIIb, open-label, multinational

Boehringer Ingelheim Initiates International Head-to-Head HIV/AIDS ...  -  May 9, 2007
Earthtimes.orgBothagents will be combined with a background regimen including tenofovir andemtricitabine (Truvada(R)). The ArTEN trial will enroll 561

Gilead: 'Best-in-class' franchise  -  May 5, 2007
Blogging StocksTruvada, which accounted for 41% of GILD's product sales, led the way with a 39% year-over-year increase in sales." He points out that Atripla is the

Boehringer Ingelheim launches HIV drug trial  -  May 10, 2007
Forbes,...will compare the efficacy of Viramune with that of protease inhibitor treatment Atazanavir/Ritonavir, both in combination with HIV treatment Truvada.

Boehringer Ingelheim launches HIV drug trial  -  May 10, 2007
Hemscott,Viramune with that of protease inhibitor treatment Atazanavir/Ritonavir, both in combination with HIV treatment Truvada. krysia.diver@thomson.com kd/jr.

Novartis Will Wait Until Indian Court Issues Decision In Patents ...  -  May 18, 2007
Medical News Today (press release),Under Gilead's proposals, generic drug companies would be allowed to sell generic versions of the antiretrovirals -- including Truvada and Viread -- only in

Royalty Pharma Acquires a Portion of New York University's Royalty ...  -  May 4, 2007
PR Newswire (press release),Amgen's Neupogen(R) and Neulasta(R), Genentech's Rituxan(R), Gilead's Emtriva(R), Truvada(R) and Atripla(R), and Celgene's Thalomid(R).

Royalty Pharma and InNexus Biotechnology Announce Agreement ...  -  Apr 26, 2007
Business Wire (press release),...including Abbott’s Humira®, Amgen’s Neupogen® and Neulasta®, Genentech’s Rituxan®, Gilead’s Emtriva®, Truvada® and Atripla®, and Celgene’s Thalomid®.

Tenofovir and Truvada licensed in South Africa  -  26 Apr 2007
Aidsmap,Tenofovir (Viread) and Truvada will be manufactured and marketed in South Africa by Aspen Pharmacare, which holds a non-exclusive voluntary license for the

Royalty Pharma and InNexus Biotechnology Announce Agreement ...  -  26 Apr 2007
Genetic Engineering News (press release),Amgen's Neupogen(R) and Neulasta(R), Genentech's Rituxan(R), Gilead's Emtriva(R), Truvada(R) and Atripla(R), and Celgene's Thalomid(R).

Royalty Pharma and InNexus Biotechnology Announce Agreement ...  -  26 Apr 2007
Business Wire (press release),...including Abbott’s Humira®, Amgen’s Neupogen® and Neulasta®, Genentech’s Rituxan®, Gilead’s Emtriva®, Truvada® and Atripla®, and Celgene’s Thalomid®.

Gilead's Atripla, Lower Costs Provide Lift To First Quarter  -  Apr 22, 2007
BioWorld Online,Gilead Sciences Inc.'s HIV steamroller charged on, helped by strong sales of Atripla in the first quarter (though Truvada and Viread dipped) plus lowered

Gilead Sciences profit surges 55%  -  Apr 18, 2007
MarketWatchThe FDA approved Atripla, made up of Gilead's Truvada -- which consists of the company's drugs Viread and Emtriva -- and Bristol-Myers Squibb Co.'s (BMY :

Analysis: Gilead's future looks bright  -  Apr 19, 2007
United Press InternationalGilead attributed product sales, which jumped 50 percent to $840.2 million, to the strong uptake of Atripla in the United States and Truvada in Europe.

Gilead Sciences Announces First Quarter 2007 Financial Results  -  Apr 19, 2007
PharmaLive.com (press release),Truvada sales were $345.9 million for the first quarter of 2007, an increase of 39 percent from $248.9 million in the first quarter of 2006.

Gilead Q1 Profit Soars 55% On Strong HIV Drug Sales  -  Apr 18, 2007
Trading Markets,Gilead's portfolio of HIV drugs includes Truvada, Atripla, Viread and Emtriva. The company's HIV product sales for the recent first quarter was $705.1

Zacks Analyst Blog Highlights: Tweeter, Best Buy, Gilead Sciences ...  -  Apr 20, 2007
Business Wire (press release),The product combines Gilead's Truvada, itself a fixed-dose combination of Viread and Emtriva, and Sustiva, a non-nucleoside reverse transcriptase inhibitor

Gilead earnings, revenue beat expectations  -  Apr 18, 2007
CNNMoney.comGilead chief operating officer John Milligan said, on a call with analysts and reporters, that earnings were driven by HIV drugs Atripla, Truvada and Viread

Gilead first quarter profit rises 55 pct  -  Apr 18, 2007
ReutersSales of HIV drugs rose 56 percent to $705.1 million, including $345.9 million for the two-drug combination HIV pill Truvada, and $190.2 million for Atripla

Gilead Profit Soars 55% on Sales of Costly HIV Drugs (Update2)  -  Apr 18, 2007
BloombergSales of Truvada, which patients take in combination with other HIV medications, rose 39 percent to $345.9 million. Truvada sells wholesale for $779 a month

Gilead quarterly profit, revenue seen up 43%  -  Apr 17, 2007
MarketWatchTruvada sales are expected to come in higher as well, at $346.8 million compared with $337.1 million in the fourth quarter. Viread and Emtriva sales,

Ahead of the Bell: Gilead Sciences  -  Apr 19, 2007
Forbes,HIV drugs Atripla and Truvada drove improved product sales. Jefferies & Co. analyst Eun Yang reiterated a "Buy" rating on the stock, and raised the firm's

TECH TICKER  -  Apr 19, 2007
San Jose Mercury News,Gilead's biggest selling HIV drug was Truvada, which accounted for $345.9 million in sales. Atripla - the nation's first once-a-day pill combining three HIV

Gilead Sciences 1Q profits up 55%  -  Apr 19, 2007
newratings.com...climbed 50% to a record $840.2 million, with growth being driven by the company’s HIV product franchise, including Atripla in the US and Truvada in Europe.

Gilead Posts 55% Q1 Profit Rise  -  Apr 19, 2007
Seeking Alpha,HIV drug sales were up 56% to $705.1 million, including $345.9 million for the combination HIV pill Truvada and $190.2 million for the once-daily pill

Gilead Sciences 1st-Quarter Profit Jumps  -  Apr 18, 2007
Forbes,...to $840.2 million, from $559.4 million a year ago, helped by sales of the company's HIV treatments, including Atripla in the US and Truvada in Europe.

AIDS drug maker for the world producing around the clock at city plant  -  Apr 13, 2007
Edmonton Journal (subscription),Its four current AIDS drugs -- Viread, Emtriva, Truvada and Atripla -- were also launched from Edmonton and contributed more than $2 billion US to the

Changing of the guard in HIV treatment  -  Apr 12, 2007
Pharmaceutical Business ReviewOf the recently launched products, Atripla, a fixed dose combination of Truvada and Sustiva, has been the first drug to combine the components of highly

3 More Kings of Cash  -  Apr 23, 2007
Motley FoolAs the world's leader in HIV treatments, Gilead's dominant franchise of products (Altripla, Truvada, Viread, and Emtriva), lengthy patent protection,

NEWS RELEASE  -  Apr 23, 2007
Financial News USA (press release),HIV drugs Atripla and Truvada drove improved product sales. Invitrogen Corporation (Nasdaq:IVGN) recently announced that Gregory T. Lucier,

AbelsonTaylor Expands Account Services with Two New Hires  -  Apr 20, 2007
PharmaLive.com (press release),Dan Lathitham, 31, will manage the agency’s account for Gilead’s Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV.

Gilead Sciences' Profit Surges 55% in Latest Quarter and CV ...  -  Apr 20, 2007
Financial News USA (press release),Gilead's HIV franchise turned in sales of $705.1 million, including $345.9 million in sales of Truvada. MedImmune, Inc. (Nasdaq: MEDI) and Micromet,

Gilead's revenue and profit up in Q1  -  Apr 19, 2007
Bizjournals.com,Truvada sales during the quarter were $345.9 million, compared with sales of $248.9 million a year ago. That drug accounted for 41 percent of Gilead's total

HIV drugs should give big boost to Gilead  -  Apr 18, 2007
CNNMoney.comReddoch also projected a surge in sales for Gilead's HIV blockbuster Truvada to $343 million in the first quarter of 2007, and $1.4 billion for the full

Earnings Preview: Gilead Sciences  -  Apr 16, 2007
Forbes,Also, sales of Atripla are expected to grow throughout the year, but could eat into sales of Gilead's other HIV drugs Viread and Truvada.

Gilead shifts Irish ops  -  Apr 13, 2007
BiopharmaReporter.com,Major products for the company include Atripla (efavirenz, emtricitabine, tenofovir), the only once-daily single tablet regimen for HIV-1 infection, Truvada

AIDS drugs sales seen topping $10 billion by 2015  -  Apr 12, 2007
Scientific AmericanAtripla was launched in the United States last year and is expected to take market share from its two components Truvada and Sustiva, as well as competitor

Billion dollar babies—biotech drugs as blockbusters  -  Apr 3, 2007
Nature.com (subscription),Truvada (emtricitabine and tenofovir), the latter two achieving blockbuster status for the first time (Table 1 and Supplementary Table 1 online).

Gilead Sciences: Rapid Growth Expected From New Products  -  Apr 3, 2007
Seeking Alpha,...and continued strong performance of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Viread (tenofovir disoproxil fumarate),

Atripla enters Kenyan market  -  27 Mar 2007
Africa Science News Service,Apola says Atripla is a fixed dose combination of efavirenz 600 mg (STOCRIN) and emtricitabine 200 mg + tenofovir 300 mg (TRUVADA).

Gilead CEO Martin Receives $13.7 Million  -  Mar 23, 2007
Forbes,...based Gilead, which makes HIV drugs Truvada, Viread and Emtriva as well as partnering with Bristol-Myers Squibb (nyse: BMY - news - people ) on the

Gilead CEO Martin Receives $13.7 Million  -  Mar 23, 2007
Houston Chronicle,...based Gilead, which makes HIV drugs Truvada, Viread and Emtriva as well as partnering with Bristol-Myers Squibb on the combination HIV drug Atripla,

Gilead promotes two execs, including CFO  -  Mar 10, 2007
Bizjournals.com,Gilead sells the antiretroviral drugs Truvada, Viread and Emtriva. Viread has been sold in the United States since 2001, Emtriva since 2003 and Truvada

CDC: AIDS drugs hold promise for prevention  -  Mar 1, 2007
Inside Bay Area,By contrast, the CDC reported new data Monday showing that two of six other monkeys became infected after receiving Truvada with about a third less dose of

New Data on Investigational Agent TMC278 in Anitretroviral-Naive ...  -  Mar 23, 2007
Drug Newswire (press release),75mg (N=95) and 150mg (N=91) -- and efavirenz (EFV) 600mg (N=89) are studied in combination with investigator- selected Combivir (R) or Truvada(R).

Avexa: trial success creates takeover speculation  -  Mar 22, 2007
Pharmaceutical Business ReviewFixed-dose combinations (FDCs) of NRTIs such as Gilead's Truvada (tenofovir/emtricitabine) and GSK's Combivir (lamivudine/zidovudine) are popular as they

CROI: New NNRTI, TMC278, demonstrates sustained potency, better ...  -  Mar 2, 2007
Aidsmap,All NRTIs were investigator-selected: 76% received Combivir and 24% received Truvada. All four arms had a similar distribution of patient demographics.

CROI 2007: A great leap forward  -  Mar 21, 2007
NAPWA,...randomised to receive one of three different doses of TMC-278 or efavirenz, in combination with a nucleoside backbone of either Combivir or Truvada.

New Drugs Lift Gilead Shares  -  Mar 20, 2007
Forbes,..."Gilead has steadily gained share in US HIV market with the launch of Atripla and the sustained market presence of Truvada," he wrote in a note to investors

Management Reshuffles - Weekly Recap  -  Mar 11, 2007
Trading Markets,The company's sales have doubled in the past two tears from $1.32 billion in 2004 $3.03 billion last year on the strength of AIDS drugs Atripla and Truvada.

New risk with hepatitis B drug  -  Mar 15, 2007
Bay Area Reporter,The resistance point also impacts use of the combination drugs Combivir, Truvada, and Atripla. During the question portion of the session, Bristol-Myers

HIV market: collaborative combinations  -  Mar 13, 2007
Pharmaceutical Business ReviewGSK's Combivir (lamivudine and zidovudine) or Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate) are potential candidates for such a

New Data On Investigational Agent TMC278 In Anitretroviral-Naïve ...  -  Mar 12, 2007
Medical News Today (press release),75 mg (N=95) and 150 mg (N=91) and efavirenz (EFV) 600mg (N=89) are studied in combination with investigator-selected Combivir® or Truvada®.

New Data on Investigational Agent TMC278 in Anitretroviral-Naive ...  -  Mar 1, 2007
PR-Inside.com (Pressemitteilung),75mg (N=95) and 150mg (N=91) -- and efavirenz (EFV) 600mg (N=89) are studied in combination with investigator-selected Combivir (R) or Truvada(R).

Anti-HBV drug entecavir also active against HIV and promotes ...  -  Mar 1, 2007
Aidsmap,...is a component of the Combivir, Trizivir and Epzicom fixed-dose combination pills, whilst emtricitabine is included in the Truvada and Atripla pills.

South Africa: Aspen's Operating Profit Lifts On Aids Drugs Sales  -  Feb 27, 2007
AllAfrica.com,He said Aspen hoped to get two second-line AIDS treatments, Truvada and Viread, registered with the Medicines Control Council by mid-year, and manufacture

Aspen revenue almost R2billion  -  Feb 26, 2007
Business Day,...let’s call that non-South African ARVs, where there’s big growth with the registration of Viread and Truvada as second-line treatments into Africa.

Aspen posts solid H1 results, headline EPS rise 11%  -  Feb 26, 2007
Engineering News (press release),Viread and Truvada, originator products, which were second line treatments, would both be launched into African markets by Aspen before the end of the

Aspen pumps up earnings 11%  -  Feb 26, 2007
iAfrica.com,Viread and Truvada, originator products which are leading second line treatments, will both be launched into African markets by Aspen before the end of the

APN - Aspen - Interim financial results: six months ended 31 ...  -  Feb 26, 2007
Finance24,Viread and Truvada, originator products which are leading second-line treatments, will both be launched into African markets before the end of the financial

Zacks Analyst Blog Highlights: Home Depot, Lowe’s, Gilead Sciences ...  -  Feb 22, 2007
Business Wire (press release),We remain optimistic about growth of HIV/AIDS franchise drugs Truvada and the recently approved Atripla. Fourth quarter earnings were above expectations

Merck & Co., Inc. To Distribute ATRIPLA™ in Developing Countries  -  Feb 16, 2007
WebWire (press release),The compounds are commonly prescribed together as a once-daily, fixed-dose tablet, marketed under the tradename Truvada®.

Gilead Sciences "buy"  -  Feb 22, 2007
newratings.comGilead Sciences’ both Truvada and Viread products are unlikely to witness competition over the next several years, Montgomery & Co adds.

Merck & Co., Inc. (1) To Distribute ATRIPLA(TM) in Developing ...  -  Feb 16, 2007
Genetic Engineering News (press release),ATRIPLA, Truvada, Viread and Emtriva are not indicated for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of these

Gilead Shares Jump on Analyst Initiation  -  Feb 21, 2007
Forbes,..."Atripla has gained significant commercial traction," Shenouda said, commenting that it, along with Truvada, account for most of the market for starts in

- Fourth Quarter Net Loss Per Share of $(3.62); Fourth Quarter Non ...  -  Feb 1, 2007
boerse.de (Pressemitteilung),Truvada sales were $337.1 million for the fourth quarter of 2006, a 76 percent increase from $191.1 million in the fourth quarter of 2005.

Gilead Sciences Revs Growth Engine  -  Feb 1, 2007
TheStreet.comTruvada sales were $337.1 million for the quarter, up 76% from the year-ago quarter. US sales of Truvada were $196.3 million, a scant 2.5% sequential drop.

Street impressed by Gilead  -  Feb 2, 2007
Monsters and Critics.com,Sales were driven by a strong performance from its HIV drugs Atripla and Truvada. Atripla racked up sales of $137 million, and Truvada generated $141

Earnings Preview: Gilead Sciences  -  Jan 29, 2007
Forbes,Merrill Lynch analyst Eric Ende also pointed out Atripla and Truvada as the key drivers for profit during the quarter. But recent acquisitions could cut

Zacks Analyst Blog Highlights: Gilead Sciences, GlaxoSmithKline ...  -  Feb 5, 2007
Business Wire (press release),We are increasing our uptake model as Atripla seems to be cannibalizing Truvada and dominating Glaxo’s (NYSE: GSK) Combivir even faster than we expected.

Gilead Q4 Report: Preview of Great Things to Come  -  Feb 12, 2007
24/7 Wall St.,Atripla and Truvada (both HIV treatments) showed no signs of canibalization which should continue in 07. - In 2007, Gilead is planning to launch products

Gilead posts fourth-quarter net loss  -  Jan 31, 2007
ReutersSales of HIV drugs rose 67 percent to $642.2 million, including $337.1 million for the two-drug combination HIV pill Truvada, and $137.4 million for Atripla

Gilead Posts 4Q Loss on Buyout Charges  -  Jan 31, 2007
Houston Chronicle,Truvada sales reached $337.1 million during the quarter, marking a 76 percent increase from the previous fourth quarter and accounting for half of the sales

Gilead Sciences swings to quarterly loss  -  Jan 31, 2007
MarketWatchThe FDA approved Atripla, which contains Bristol-Myers' Sustiva and Gilead's Truvada, which itself consists of the company's drugs Viread and Emtriva,

New AIDS drugs aim to combat resistant HIV strains  -  Feb 23, 2007
The Advocate,On Wednesday, Gilead Sciences, maker of top-selling HIV pill Truvada, will present data from a midstage trial of its experimental integrase inhibitor

Glad Tidings for Gilead  -  Feb 1, 2007
BusinessWeekThe company also sells Truvada which contains two of those three medicines and Viread which contains one. Atripla adds the Bristol-Myers Squibb (BMY) drug

Gallant Gilead Sciences: Fool by Numbers  -  Feb 1, 2007
Motley Fool...by 55.7% to $768.1 million, primarily thanks to a 67% increase in the HIV product franchise and the strong performance of the Atripla and Truvada drugs.

Gilead Sciences "buy," target price raised  -  Feb 1, 2007
newratings.comEPS ahead of the estimates and the consensus due to higher-than-anticipated royalties and revenues from the sales of the Truvada and Atripla drugs.

Merck to register, lower cost of antiretroviral Atripla in ...  -  Feb 21, 2007
News-Medical.net,Atripla, which was approved by FDA in July 2006, combines Bristol-Myers Squibb's Sustiva and Gilead's Truvada into a single pill.

Merck To Register, Lower Cost of Antiretroviral Atripla in ...  -  Feb 21, 2007
Kaiser network.org,Atripla, which was approved by FDA in July 2006, combines Bristol-Myers Squibb's Sustiva and Gilead's Truvada into a single pill. Merck and Gilead in August

Merck, Pfizer HIV Drugs May Spark a Second Revolution (Update1)  -  Feb 15, 2007
BloombergThe maker of the top-selling Truvada HIV drug, Foster City, California-based Gilead Sciences Inc., is also developing an integrase inhibitor like Merck's.

Strong quarter boosts Gilead  -  Feb 12, 2007
Blogging StocksHe explains, "Gilead's HIV treatments (Viread, Truvada, Atripla, and Emtriva) were clear winners, with sales growing 67% to $642.4 million and surpassing

Gilead Sciences Shares Peak on 4Q Profit  -  Feb 1, 2007
Houston Chronicle,Truvada sales reached $337.1 million during the quarter, marking a 76 percent increase. Viread sales fell 13 percent to $159.5 million, and Atripla sales

Gilead Sciences Posts Q4 Loss On Charges; EPS Beats View; Stock Up ...  -  Jan 31, 2007
Trading Markets,Truvada's sales increased 76% to $337.1 million for the quarter, while Viread sales dropped 13% to $159.5 million. Atripla contributed $137.4 million,

Research and Markets : Changewave Report Examines The Concerns ...  -  18 Jan 2007
PharmaLive.com (press release),Are Doctors likely to prescribe the Sustiva/Truvada combination drug? -- When it comes to cost of medications and insurance coverage for Hepatitis C and

Gilead Sciences "outperform," target price raised  -  Jan 3, 2007
newratings.comIn a research note published this morning, the analyst mentions that Atripla has been able to gain market share faster than the rate witnessed with Truvada.

Top Picks 2007: Bill Martin "finds profits" at Gilead  -  Dec 27, 2006
Blogging StocksThe advisor explains, "Gilead is best known as a biopharmaceutical company with a leading HIV treatment franchise (Viread, Truvada, and Emtriva).

The Year in Review: Gilead Rises in 2006  -  Dec 27, 2006
Forbes,It combines Gilead's Truvada, which includes Viread and Emtriva, with Bristol-Myers Squibb (nyse: BMY - news - people )'s Sustiva and is the first

The Year In Review: Gilead rises in 2006  -  Dec 27, 2006
BusinessWeekIt combines Gilead's Truvada, which includes Viread and Emtriva, with Bristol-Myers Squibb's Sustiva and is the first once-a-day HIV treatment.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional